HIV DART 2000 Program Secretariat Corporate Support Registration
Welcome Abstract Submission

Preliminary Program

 

Lava ArchesThe HIV DART 2000 conference program covers five days, begining Sunday December 17, 2000 and ending Thursday December 21, 2000. The detailed program listing below is divided chronologically through the four days of the conference.

A one-page tabular listing of the conference sessions is also available on the Meeting Format page.

 Committee Members
General Information
Important Dates

Meeting Format

Sunday, 12/17/00 Monday, 12/18/00 Tuesday, 12/19/00 Wednesday, 12/20/00 Thursday, 12/21/00

Sunday, December 17
 
14:00 Opening Remarks and Chairs  
  Jean-Pierre Sommadossi University of Alabama at Birmingham, USA
  Joep Lange Academic Medical Centre, The Netherlands
 
14:10 Frontiers in Drug Development for Antiretroviral Therapies
  Anthony Fauci NIAID, National Institutes of Health, USA
 
15:10 Collaborative Research Seminar on HIV Entry and Fusion Inhibition
  Dani Bolognesi Trimeris, USA
 
15:50 Tipranavir: A New Class of Protease Inhibitor
  Geoff Cotton Boehringer Ingelheim/Roxane Laboratories Inc
 
19:30 Welcome Reception -- Poolside

 

 
Sunday, 12/17/00 Monday, 12/18/00 Tuesday, 12/19/00 Wednesday, 12/20/00 Thursday, 12/21/00

Monday, December 18
 
Drug Design and Discovery: Viral Targets
 
Chairs Raymond Schinazi Emory University/Atlanta VA Medical Center, USA
  Erik De Clercq Katholieke Universiteit Leuven, Belgium
 
8:00 Presentation of Gertrude Elion Distinguished Lecturer Award
  Dani Bolognesi Trimeris, USA
 
8:10 Therapeutic Agents and Viral Targets: What is on the Horizon?
  Douglas Richman University of California San Diego, USA
 
9:00 Functional genomics reveals cellular targets for antiviral drug development
  Klaus Frueh Oregon Health Science University, USA
 
9:20 Assembly and Viral Core Maturation - Novel Targets for Drug Discovery
  Eric Hunter University of Alabama at Birmingham, USA
 
9:40 Removal of Chain Terminators by HIV-1 Reverse Transcriptase
  Walter Scott University of Miami School of Medicine, USA
 
10:00 Panel Discussion
 
10:30 Morning Break
 
Oral Abstract Presentations (Mechanisms and Drug Development)
 
Chairs Franco Lori RIGHT, Washington DC & Pavia Italy
  Bruce Polsky St Luke's-Roosevelt Hospital Center & Columbia University, USA
 
11:00 Mechanisms of anti-HIV action of SJ-3366: Effects on reverse transcriptase and cell surface events
  Robert Buckheit, Jr Southern Research Institute, USA
 
11:15 Long patch base excision repair as a model for the late stages of integration of human immunodeficiency virus type 1 proviral DNA
  Emmanuel Faust SMBVD-Jewish General Hospital, Canada
 
11:30 DNA methylation in the promoter sequence of human thymidine kinase gene: analyses of HIV-positive patients receiving antiviral nucleoside analog therapy
  Xinru Pan-Zhou University of Alabama at Birmingham, USA
 
11:45 Nucleotide-dependent removal of C- and T-nucleotide analogues by wild-type and AZT-resistant HIV-1 reverse transcriptase
  Peter Meyer University of Miami, USA
 
12:00 Lunch Break
 
Chemistry and Pre-clinical Development
 
Chairs Jean-Louis Imbach University of Montpellier, France
  Martin Bryant Novirio Pharmaceuticals, USA
 
13:30 Use of Inhibitory Quotient (IQ) to Estimate the Activity of HIV Protease Inhibitors
  Akhter Molla Abbott Laboratories, USA
 
13:50 Development of SCH-C, a Small Molecule Antagonist of CCR5, as a Novel HIV Therapeutic
  Julie Strizki Schering-Plough Research Institute, USA
 
14:10 Strand Transfer Specific Inhibitors of HIV-1 Integrase
  Daria Hazuda Merck Research Labs, USA
 
14:30 Study of Mode Action of Nucleoside RT Inhibitors and Drug Resistance by Molecular Modeling Approach
  C.K. Chu University of Georgia, USA
 
14:50 NNRTIs as Candidates to Prevent Mucosal HIV Transmission
  Paolo La Colla Universita di Cagliari, Italy
 
15:10 Development of Specific Anti-HIV Microbicides
  Mark Wainberg McGill AIDS Centre, Canada
 
15:30 Panel Discussion
 
16:00 Afternoon Break
 
Oral Abstract Presentations (Pre-clinical Development)
 
Chairs Phillip Furman Triangle Pharmaceuticals, USA
  Francois Clavel Hopital Bichat Claude Bernard, France
 
16:30 BCH-10618, a new potent anti-HIV-1 NRTI
  Richard Bethell BioChem Pharma, Inc, Canada
 
16:45 Amino-terminus modified Rantes analogues as topical virustats
  Michael Lederman Case Western Reserve University, USA
 
17:00 Potent antiviral activity of Racivir TM in the HuPBMC-SCID mouse model of HIV infection
  Paul Black QuadPharma, Inc, USA
 
17:15 Structured treatment interruptions induce control of viral replication in SIV infections
  Mark Lewis Southern Research Institute, USA
 
 

 
Sunday, 12/17/00 Monday, 12/18/00 Tuesday, 12/19/00 Wednesday, 12/20/00 Thursday, 12/21/00

Tuesday, December 19
 
Viral Resistance
 
Chairs John Sullivan University of Massachusetts Medical Center, USA
  Mark Wainberg McGill AIDS Centre, Canada
 
8:00 New Developments in Antiretroviral Drug Resistance
  John Mellors University of Pittsburgh, USA
 
8:20 Use of Genotypic and Phenotypic Data For Optimal Monitoring of HIV-1 Drug Resistance
  Brendan Larder VIRCO, UK
 
8:40 Frontiers in Antiretroviral Drug Susceptibility Testing
  Christos Petropoulos ViroLogic, Inc, USA
 
9:00 Presentation
  Francois Clavel Hopital Bichat-Claude Bernard, France
 
9:20 Panel Discussion
 
9:50 Morning Break
 
Pharmacology
 
Chairs José Rodriguez University of Puerto Rico, Puerto Rico
  Arnold Fridland Gilead Sciences, Inc, USA
 
10:20 Pharmacologic Considerations for Antiretroviral Drug Development in Children
  Courtney Fletcher University of Minnesota, USA
 
10:40 Cytochrome P450 Isozymes and Drug-Drug Interaction with Antiretroviral Drugs
  John Gerber University of Colorado, USA
 
11:00 Presentation
  Richard Hoetelmans Sloltervaart Hospital, The Netherlands
 
11:20 Intracellular Studies of Nucleoside Reverse Transcriptase Inhibitor Active Metabolites in HIV-infected Patients
  José Rodriguez University of Puerto Rico, Puerto Rico
 
11:40 Panel Discussion
 
12:10 Lunch Break
 
13:30 State-of-the-Art Presentation: Clinical Aspects: Where Do We Stand?
  Joep Lange Academic Medical Centre, The Netherlands
 
Immunotherapy in HIV Infection
 
Chairs Robert Murphy Northwestern University, USA
  Martin Hirsch Massachusetts General Hospital, USA
 
14:10 Presentation
  Brigitte Autran Groupe Hospitalier Pitié-Salpetrière, France
 
14:30 An Adrenal Steroid Dervative is an Immunomodulator in HIV-infected Individuals
  Tom Merigan Stanford University, USA
 
14:50 Current Status of Immunotherapy for HIV Infection
  Richard Pollard University of Texas Medical Branch, USA
 
15:10 Immune Response in HIV Infection
  Giuseppi Pantaleo University of Lausanne, Switzerland
 
15:30 Structured Treatment Interruptions
  Franco Lori RIGHT, Washington DC & Pavia Italy
 
15:50 Afternoon Break
 
Oral Abstract Presentations (Pharmacology, microbicides, and drug resistance)
 
Chairs John Mellors University of Pittsburgh, USA
  Carlos Zala Fundación Huésped, Argentina
 
16:20 Practical curtailment of the HIV epidemic by adapting the potent oral defense to topically prevent vaginal and rectal transmission
  Samuel Baron University of Texas Medical Branch, USA
 
16:35 High prevalence of protease inhibitor resistance in Brazilian compared to US HIV-1 samples genotyped by North American reference laboratory
  Peter Heseltine Nichols Institute Quest Diagnostics, USA
 
16:50 Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug resistant reverse transcriptase
  Bruno Canard National Center of Scientific Research, France
 
17:05 Design of anti-resistance HIV-1 protease inhibitors
  Jordan Tang Oklahoma Medical Research Foundation, USA
 
17:20 Safety and efficacy of lodenosine (FddA) in combination with stavudine and indinavir in antiretroviral naïve, HIV-infected adults: Association with severe hepatotoxicity
  Benjamin Young Rose Medical Center, USA
 
17:35 Therapeutic Drug Monitoring - A Survey of the Use in Clinical Practice in the UK and Ireland
  Concepta Merry Northwestern University, USA
 
17:50 HE2000 stimulates immunity in patients with HIV
  Chris Reading Hollis-Eden Pharmaceuticals, USA
 
20:00 Fiesta Gala Event

 
Sunday, 12/17/00 Monday, 12/18/00 Tuesday, 12/19/00 Wednesday, 12/20/00 Thursday, 12/21/00

Wednesday, December 20
 
First Line Antiretroviral Therapy/Salvage Therapy
 
Chairs Julio Montaner BC Centre for Excellence in HIV Infection, Canada
  Christine Katlama Groupe Hospitalier Pitié-Salpetrière, France
 
8:00 Novel Combination Therapy Strategies
  Martin Hirsch Massachusetts General Hospital, USA
 
8:20 Ritonavir (RTV)/Indinavir (IDV) (100/400 mg bid): A Simple and Well-tolerated PI Containing Regimen
  Christine Katlama Groupe Hospitalier Pitié-Salpetrière, France
 
8:40 Selected topics on antiretroviral associated toxicity derived from a cohort study (BCN-Clinic cohort)
  José Gatell Hospital Clinic, Spain
 
9:00 Efficacy and safety of Lopinavir (ABT-378)
  Robert Murphy Northwestern University, USA
 
9:20 Morning Break
 
9:50 Survival Benefit of Antiretroviral Therapy is Compromised by Baseline CD4+ Counts Below 200 Cells/mm3 and Not by Plasma HIV-1 RNA Levels
  Julio Montaner British Columbia Centre for Excellence in HIV/AIDS, Canada
 
10:10 Antiretroviral toxicity: an increasingly important issue in the management of HIV-infected patients
  David Cooper University of New South Wales, Australia
 
10:30 Perinatal Transmission of HIV
  John Sullivan University of Massachusetts Medical Center, USA
 
10:50 Panel Discussion
 
Oral Abstract Presentations (Toxicology and Clinical Development)
 
Chairs Richard Pollard University of Texas Medical Branch
  Jorge Santana University of Puerto Rico, Puerto Rico
 
11:30 HAART treatment yields no AIDS deaths in an inner-city population over 3 years
  Gary Reiter University of Puerto Rico, PR
 
11:45 Persistent Abnormalities In Lymphoid Tissues Of Persons Showing Good Virologic Response To Antiretroviral Therapy In All Treatment Arms Of The Atlantic Study
  Timothy W Schacker University of Minnesota, USA
 
12:00 Nonadherence to triple combination therapy is predictive of mortality at baseline and after one-year of follow-up
  Robert Hogg BC Centre for Excellence in HIV/AIDS, Canada
 
12:15 Pharmacokinetic and safety evaluation of a once daily regimen of saquinavir soft gel capsules in HIV infected antiretroviral naive patients
  Julio Montaner British Columbia Centre for Excellence in HIV/AIDS, Canada
 
Regulatory Issues: Viewpoints
 
Chairs José Gatell Hospital Clinic, Spain
  Giuseppe Pantaleo University of Lausanne, Switzerland
 
12:30 Current Views on Accelerated Approval and Endpoints in Regulatory Trials
  Jeff Murray Federal Drug Administration, USA
 
12:50 Panel Discussion
  Douglas Richman and Robert Murphy, Discussants  
 
14:00 Poster Viewing/Free Afternoon
 
16:30 Poster Session with Wine and Hors d' oeuvres
 

 
Sunday, 12/17/00 Monday, 12/18/00 Tuesday, 12/19/00 Wednesday, 12/20/00 Thursday, 12/21/00

Thursday, December 21
 
HIV/Hepatitis and Other Co-infections
 
Chairs Douglas Richman University of California San Diego, USA
  Michael Otto Pharmasset, Inc, USA
 
8:00 Co-infection with HIV and Hepatitis B Virus
  Bruce Polsky St Luke Roosevelt Hospital Center & Columbia University, USA
 
8:20 Interferon (IFN) and Ribavirin (RBV) Therapy for Hepatitis C (HCV) Patients who are Co-infected with HIV: Sustained Virologic Response (SVR)
  Douglas Dieterich Cabrini Medical Center, New York University School of Medicine, USA
 
8:40 Treating Co-Infected Patients
  Maribel Rodriguez-Torres Fundación Gastroenterologia De Diego, Puerto Rico
 
9:00 Panel Discussion
 
Oral Abstract Presentations (Co-infections and Vaccines)
 
9:30 An open label pilot study of the safety and efficacy of adefovir dipivoxil in HIV/HBV co-infected patients with lamivudine resistant HBV
  Christine Katlama Groupe Hospitalier Pitié-Salpetrière, France
 
9:45 Persistent immune activation and chronic viral disease: Diagnostic and therapeutic relationship between HIV and HCV disease
  Michael McGrath University of California at San Francisco, USA
 
10:00 Induction of potent HIV-specific T cell restricted immunity by genetically-modified dendritic cells
  Julianna Lisziewicz Research Institute for Genetic and Human Therapy, USA
 
10:15 Morning Break
 
Vaccines/Therapeutic Vaccines
 
Chairs David Cooper University of New South Wales, Australia
  Eric Hunter University of Alabama at Birmingham, USA
 
10:45 HIV Vaccines: Where Are We Now?
  Lawrence Corey University of Washington at Seattle, USA
 
11:05 Vaccines and Immune Memory
  Rafi Ahmed Emory University, USA
 
11:25 Enhanced DNA, Alphavirus, and Protein Vaccine Approaches Stimulate Potent Immune Responses Against HIV Antigens
  Susan Barnett Chiron Corporation, USA
 
11:45 Strategies of Immune Evasion Used by the HIV-encoded Envelope Proteins
  Ronald Desrosiers Harvard Medical School, USA
 
12:05 Panel Discussion
 
12:30 Closing Remarks
  Jean-Pierre Sommadossi
  Joep Lange  

Return to Top of Page
|
Return to Home Page

Copyright © 2000 Informed Horizons, LLC
Designed by Virginia-Highland Software, Inc.
All rights reserved, additional copyright information also applies.